PL3856742T3 - Trójcykliczne inhibitory kinazy janusowej 1 oraz ich kompozycje i sposoby - Google Patents
Trójcykliczne inhibitory kinazy janusowej 1 oraz ich kompozycje i sposobyInfo
- Publication number
- PL3856742T3 PL3856742T3 PL19878002.5T PL19878002T PL3856742T3 PL 3856742 T3 PL3856742 T3 PL 3856742T3 PL 19878002 T PL19878002 T PL 19878002T PL 3856742 T3 PL3856742 T3 PL 3856742T3
- Authority
- PL
- Poland
- Prior art keywords
- tricyclic
- inhibitors
- compositions
- methods
- janus kinase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862754029P | 2018-11-01 | 2018-11-01 | |
| PCT/CN2019/115069 WO2020088659A1 (en) | 2018-11-01 | 2019-11-01 | Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3856742T3 true PL3856742T3 (pl) | 2025-02-17 |
Family
ID=70464625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19878002.5T PL3856742T3 (pl) | 2018-11-01 | 2019-11-01 | Trójcykliczne inhibitory kinazy janusowej 1 oraz ich kompozycje i sposoby |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US12024516B2 (pl) |
| EP (2) | EP3856742B1 (pl) |
| JP (2) | JP7651457B2 (pl) |
| KR (1) | KR102841141B1 (pl) |
| CN (2) | CN113396150B (pl) |
| AU (2) | AU2019372677B2 (pl) |
| BR (1) | BR112021008128A2 (pl) |
| CA (1) | CA3115897A1 (pl) |
| ES (1) | ES2993867T3 (pl) |
| IL (1) | IL282786B1 (pl) |
| MX (1) | MX2021004517A (pl) |
| PL (1) | PL3856742T3 (pl) |
| SG (1) | SG11202103694UA (pl) |
| TW (1) | TWI842766B (pl) |
| WO (1) | WO2020088659A1 (pl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3856742B1 (en) * | 2018-11-01 | 2024-10-02 | Lynk Pharmaceuticals Co. Ltd. | Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof |
| CN113637018A (zh) * | 2020-04-27 | 2021-11-12 | 苏州晶云药物科技股份有限公司 | 磺酰胺类化合物的晶型及其制备方法 |
| EP4211132A1 (en) | 2020-09-08 | 2023-07-19 | Galderma Holding SA | Novel jak inhibitor compounds, method for synthesizing same and use thereof |
| CN116925077A (zh) * | 2020-09-08 | 2023-10-24 | 一又生物(上海)有限公司 | 吡啶并环类化合物及其制备方法、中间体、组合物和应用 |
| WO2022054005A1 (en) * | 2020-09-14 | 2022-03-17 | Galderma Holding SA | Novel jak inhibitor compounds, method for synthesizing same and use thereof |
| JP7688449B2 (ja) * | 2021-12-21 | 2025-06-04 | イーヨウ バイオテック （シャンハイ） カンパニー リミテッド | ピリジン縮合環系化合物とその製造方法、中間体、組成物及び使用 |
| WO2025102268A1 (en) * | 2023-11-15 | 2025-05-22 | Lynk Pharmaceuticals Co. Ltd. | Solid state forms, pharmaceutical compositions, preparation methods and use thereof |
| WO2025157232A1 (zh) * | 2024-01-26 | 2025-07-31 | 凌科药业(杭州)有限公司 | 并环化合物的制备方法及其中间体 |
| WO2025167710A1 (zh) * | 2024-02-08 | 2025-08-14 | 凌科药业(杭州)有限公司 | 三稠环化合物在制备预防和/或治疗炎性疾病药物中的应用 |
| TW202602438A (zh) * | 2024-03-21 | 2026-01-16 | 大陸商凌科藥業有限公司 | 藥物成分、劑型及其製備及使用方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| ATE141502T1 (de) | 1991-01-15 | 1996-09-15 | Alcon Lab Inc | Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| WO2007005643A2 (en) | 2005-07-01 | 2007-01-11 | Concert Pharmaceuticals Inc. | Novel aryloxyphenylpropanamines |
| WO2007005644A2 (en) | 2005-07-01 | 2007-01-11 | Concert Pharmaceuticals Inc. | Novel aryloxypropanamines |
| CA2616383C (en) | 2005-07-29 | 2015-06-09 | Concert Pharmaceuticals Inc. | Novel benzo[d][1,3]-dioxol derivatives |
| AU2006275702A1 (en) | 2005-07-29 | 2007-02-08 | Concert Pharmaceuticals Inc. | Novel pharmaceutical compounds |
| JP5748659B2 (ja) | 2008-06-10 | 2015-07-15 | アッヴィ・インコーポレイテッド | 新規な三環式化合物 |
| DE102009033309B4 (de) * | 2009-07-15 | 2019-08-14 | Continental Automotive Gmbh | Tragbare Fernbedienungsvorrichtung |
| PE20121336A1 (es) | 2009-12-01 | 2012-11-03 | Abbvie Inc | Nuevos compuestos triciclicos |
| EP2523957A1 (en) | 2010-01-12 | 2012-11-21 | F. Hoffmann-La Roche AG | Tricyclic heterocyclic compounds, compositions and methods of use thereof |
| WO2013007765A1 (en) * | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Fused tricyclic compounds for use as inhibitors of janus kinases |
| EP2924026A1 (en) | 2014-03-28 | 2015-09-30 | Novartis Tiergesundheit AG | Aminosulfonylmethylcyclohexanes as JAK inhibitors |
| EP3856742B1 (en) * | 2018-11-01 | 2024-10-02 | Lynk Pharmaceuticals Co. Ltd. | Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof |
-
2019
- 2019-11-01 EP EP19878002.5A patent/EP3856742B1/en active Active
- 2019-11-01 TW TW108139784A patent/TWI842766B/zh active
- 2019-11-01 MX MX2021004517A patent/MX2021004517A/es unknown
- 2019-11-01 PL PL19878002.5T patent/PL3856742T3/pl unknown
- 2019-11-01 CA CA3115897A patent/CA3115897A1/en active Pending
- 2019-11-01 CN CN201980070833.6A patent/CN113396150B/zh active Active
- 2019-11-01 ES ES19878002T patent/ES2993867T3/es active Active
- 2019-11-01 EP EP24203880.0A patent/EP4520395A3/en active Pending
- 2019-11-01 JP JP2021525022A patent/JP7651457B2/ja active Active
- 2019-11-01 SG SG11202103694UA patent/SG11202103694UA/en unknown
- 2019-11-01 KR KR1020217013443A patent/KR102841141B1/ko active Active
- 2019-11-01 AU AU2019372677A patent/AU2019372677B2/en active Active
- 2019-11-01 US US17/289,584 patent/US12024516B2/en active Active
- 2019-11-01 CN CN202410365627.0A patent/CN118406052A/zh active Pending
- 2019-11-01 WO PCT/CN2019/115069 patent/WO2020088659A1/en not_active Ceased
- 2019-11-01 BR BR112021008128-3A patent/BR112021008128A2/pt unknown
-
2021
- 2021-04-29 IL IL282786A patent/IL282786B1/en unknown
-
2023
- 2023-06-30 US US18/217,037 patent/US11851431B2/en active Active
- 2023-06-30 US US18/217,009 patent/US11858933B2/en active Active
-
2024
- 2024-05-20 US US18/669,184 patent/US12516061B2/en active Active
- 2024-07-17 JP JP2024113808A patent/JP2024147699A/ja active Pending
- 2024-08-14 AU AU2024205760A patent/AU2024205760A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202103694UA (en) | Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof | |
| IL276082B1 (en) | DNA-pk inhibitor compounds, preparations containing them and their uses | |
| IL276080A (en) | DNA-pk suppressor compounds, UTP-containing preparations and their uses | |
| SA520411990B1 (ar) | مركبات مفيدة لتثبيط إنزيم كيناز 7 المعتمد على السيكلين | |
| IL285302A (en) | Compounds, preparations and methods | |
| SG11202104326TA (en) | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors | |
| SG11202011513RA (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| EP3672973A4 (en) | HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS, COMPOSITIONS INCLUDING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | |
| IL273300A (en) | High dose valbenazine formulation and related preparations, methods and kits | |
| IL276269A (en) | Aminopyrrolotriazines as kinase inhibitors | |
| WO2016044463A3 (en) | Mk2 inhibitors and uses thereof | |
| IL278758A (en) | VMAT2 inhibitory compounds, compositions and methods related thereto | |
| ZA201906887B (en) | Bruton's tyrosine kinase inhibitors | |
| IL283599A (en) | Tyrosine kinase inhibitors, preparations and methods | |
| IL267829B (en) | History of new amino-imidazopyridines as Janus kinase inhibitors and their pharmaceutical use | |
| IL269701A (en) | Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof | |
| IL287120A (en) | Compounds, preparations and methods | |
| ZA202102261B (en) | Spak kinase inhibitors as neuroprotective agents | |
| WO2018166993A3 (en) | PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | |
| EP3327021A4 (en) | Janus kinase 1 selective inhibitor and pharmaceutical use thereof | |
| EP3831829A4 (en) | CDK8/19 INHIBITORS | |
| ZA202104192B (en) | Mmpl3 inhibitors, compositions and uses thereof | |
| EP3607944A4 (en) | NEW INHIBITOR OF THE CYCLINE-DEPENDENT KINASE 8 AND / OR 19 | |
| ZA202103858B (en) | Tyrosine kinase inhibitors, compositions and methods there of |